Henry Ford Health System

Henry Ford Health System Scholarly Commons
Case Reports

Medical Education Research Forum 2020

5-2020

p-16: immunohistochemical staining to differentiate an inflamed
atypical nevus
Madeline Adelman
Henry Ford Health System, madelma1@hfhs.org

Alexis B. Lyons
Henry Ford Health System, ALyons5@hfhs.org

Lauren Seale
Henry Ford Health System, lseale2@hfhs.org

Ben J. Friedman
Henry Ford Health System, bfriedm1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/merf2020caserpt

Recommended Citation
Adelman, Madeline; Lyons, Alexis B.; Seale, Lauren; and Friedman, Ben J., "p-16: immunohistochemical
staining to differentiate an inflamed atypical nevus" (2020). Case Reports. 122.
https://scholarlycommons.henryford.com/merf2020caserpt/122

This Poster is brought to you for free and open access by the Medical Education Research Forum 2020 at Henry
Ford Health System Scholarly Commons. It has been accepted for inclusion in Case Reports by an authorized
administrator of Henry Ford Health System Scholarly Commons.

p-16 immunohistochemical staining to differentiate an inflamed atypical nevus from
metastatic melanoma
Madeline Adelman BS,¹ Alexis B. Lyons MD,2 Lauren Seale MD,2 Ben Friendman MD²
¹Wayne State University School of Medicine
² Department of Dermatology, Henry Ford Hospital

Solution

Clinical Challenge
• A 45-year-old white female with a history of metastatic
melanoma to the left supraclavicular lymph node from
an unknown primary melanoma on nivolumab presented
to clinic
• There was a new pink papule with irregular vascularity
on her right upper arm. (Fig 1)
• Histopathology revealed small nests of melanocytes in
the dermis with a brisk lymphocytic infiltrate and rare
dermal mitotic figures, (Fig 2) consistent with either an
inflamed atypical intradermal nevus secondary to
immunotherapy or a cutaneous metastatic melanoma
site.
• Although histopathology is the gold standard for
melanoma diagnosis, distinguishing between these two
entities in this clinical setting requires further
investigation.

• To help differentiate an inflamed melanocytic nevus with
atypical features from a cutaneous melanoma metastasis
in this setting, immunohistochemical staining for the
tumor suppressor p16 can be utilized.
• One of the major genetic defects linked to melanoma
pathogenesis is a mutation or deletion of the CDKN2A
gene, which encodes for p16.1
• Loss of p16 expression results in unregulated cell-cycle
progression.
• Several studies have demonstrated a frequent reduction in
p16 expression in primary sporadic melanomas, and an
even higher frequency of reduction in melanoma
metastasis.2
• Given this, the patient’s original lymph node melanoma
sample and the biopsy from the right upper arm were
stained for p16 (Fig 2).
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Solution Continued
• The new papule on the arm demonstrated preservation of
p16, while the previous melanoma showed a loss of p16.
• Thus, this helped confirm that the new lesion was an
inflamed melanocytic nevus secondary to treatment with
nivolumab.

Discussion
• In the monitoring of patients who have had metastatic
melanoma, repeat skin exams at specific intervals is a crucial
screening tool to prevent recurrence.
• At many of these visits, suspicious melanocytic lesions are
biopsied to determine if they represent a return of the
patient’s melanoma.
• Here, we present a case of a suspicious atypical melanocytic
nevus discovered during a skin exam following diagnosis of
metastatic melanoma to a lymph node from an unknown
primary lesion.
• To determine whether this lesion was melanoma, p16
immunohistochemical staining was performed of both the
lymph node biopsy and the nevus, and provided a reliable
means for determining the nature of the nevus.
• This information would be helpful to readers who care for
patients with a history of melanoma who require
differentiation of atypical nevi from recurrence of
melanoma.
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Figure 1: Pink papule on the right upper arm

Figure 2. A) Inflamed melanocytic nevus with atypical features with positive p16
staining. B) Initial lymph node with metastatic melanoma of unknown primary
with negative p16 staining
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